ATLANTA, GA--(MARKET WIRE)--Aug 29, 2007 -- AtheroGenics, Inc. (NasdaqGM:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that new scientific data of its oral antidiabetic agent AGI-1067 has been accepted for an oral presentation in a Hotline & Clinical Update session at the upcoming European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria.
